Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1007839

registered interest
date	15/11/2018
answering body	Home Office
answering dept id	1
answering dept short name	Home Office
answering dept sort name	Home Office
hansard heading	National Economic Crime Centre
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for the Home Department, how the National Economic Crime Centre is planned to help increase the number of prosecutions for crimes such as bribery and corruption.
tabling member constituency	Hendon
tabling member printed	Dr Matthew Offord
uin	191903
answer	answer is ministerial correction date of answer 23/11/2018 answer text <p>The National Economic Crime Centre (NECC) will deliver a step change in the UK's response to - and impact on economic crime, including bribery and corruption.</p><p>For the first time, the NECC brings together enforcement and justice agencies (HM Revenue and Customs, the City of London Police, the National Crime Agency, the Serious Fraud Office and the Crown Prosecution Service), other government departments, regulatory bodies and the private sector with a shared objective of driving down economic crime in the UK.</p><p>It will leverage the 'whole system' approach to enhance and coordinate our collective capabilities to target, pursue and dismantle the highest harm serious and organised criminals, including corrupt elites. Where appropriate this will include prosecutions.</p> answering member constituency Wyre and Preston North answering member printed Mr Ben Wallace question first answered 23/11/2018 12:12:03 answering member 1539 label Biography information for Mr Ben Wallace
tabling member	4006 label Biography information for Dr Matthew Offord

1007797

registered interest
date	15/11/2018
answering body	Department for Exiting the European Union
answering dept id	203
answering dept short name	Exiting the European Union
answering dept sort name	Exiting the European Union
hansard heading	Department for Exiting the European Union: Labour Turnover
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Exiting the European Union, what estimate he has made of the number of staff who have left his Department since it was created; and what information his Department holds on the reasons for those departures.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	191861
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>The Department for Exiting the European Union was set up as a time limited department and as such the majority of staff are employed on fixed term contracts or are loaned from other Government Departments. Attrition has remained stable at about 3% monthly average for most of the department’s life. These figures are not considered out of line for a department that has a staff profile as above. Many of those who have left to date have been planned leavers who have moved to other government departments due to their loan or job rotation coming to an end.</p><p> </p> answering member constituency Worcester answering member printed Mr Robin Walker question first answered 20/11/2018 16:27:03 answering member 4091 label Biography information for Mr Robin Walker
tabling member	308 label Biography information for Mr Jim Cunningham

1007757

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Levetiracetam
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the effect of the UK leaving the EU on the availability of Keppra for people with epilepsy.
tabling member constituency	Crewe and Nantwich
tabling member printed	Laura Smith
uin	191984
answer	answer is ministerial correction date of answer 22/11/2018 answer text <p>The United Kingdom’s position on medicines regulation remains clear. We want to retain a close working partnership with the European Union to ensure that medicines remain available to UK patients in a safe and timely manner. We have been clear that this involves us making sure our regulators continue to work together, as they do with regulators internationally. As the Prime Minister has said, we intend to to explore with the EU the terms on which the UK could remain part the European Medicines Agency.</p><p> </p><p>Until we can be certain of the outcome of Brexit negotiations our duty as a responsible Government is to prepare for all eventualities, including ‘no deal’. On 23 August 2018, therefore, the Department wrote to all pharmaceutical companies that supply the United Kingdom with prescription only or pharmacy medicines from, or via, the European Union/European Economic Area, asking them to ensure they have a minimum of six weeks’ additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no-deal scenario.</p><p> </p><p>Since then, we have received very good engagement from industry who share our aims of ensuring continuity of medicines supply for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal Brexit.</p><p> </p><p>We understand that the medicine Keppra is important to many people in this country. However, the Department recognises that through its medicines supply contingency programme it is requesting sensitive commercial information from pharmaceutical companies. To reassure participating companies, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme. That means not introducing information about a company, specific medicine or their supply routes into the public domain.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/11/2018 11:54:10 answering member 4067 label Biography information for Steve Brine
tabling member	4648 label Biography information for Laura Smith

1007767

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Nusinersen
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress NHS England, Biogen and NICE have made in discussions on a managed access agreement for the use of Spinraza for the treatment of spinal muscular dystrophy.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	191928
answer	answer is ministerial correction date of answer 22/11/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).</p><p> </p><p>NICE is in discussion with Biogen (the company that manufactures Spinraza) to determine if there are any commercial flexibilities that could support the company in putting forward a cost-effective price in order for NICE to recommend use of the drug as a clinically and cost-effective use of NHS resources.</p><p> </p><p>NHS England has published an Interim Policy Statement determining the circumstances in which existing patients will be supported to access Spinraza through the Expanded Access Programme (EAP) scheme sponsored by Biogen. The policy statement enables existing patients with type 1 SMA to access Spinraza in advance of NICE’s guidance, although the company has now withdrawn the EAP for newly diagnosed patients.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/11/2018 15:13:09 answering member 4067 label Biography information for Steve Brine
tabling member	4249 label Biography information for Anne Marie Morris

1007772

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, if he will publish the review of risk factors and associated vulnerabilities among women recruited to the trial.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	191929
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191930 191931 191932 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
tabling member	4267 label Biography information for Sarah Champion

1007773

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: drugs, if he will publish the outcome of the interviews with women to explore the facilitators and barriers to accessing the HIV pre-exposure prophylaxis.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	191930
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191929 191931 191932 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
tabling member	4267 label Biography information for Sarah Champion

1007775

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women have joined the HIV pre-exposure prophylaxis impact trial to date.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	191931
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191929 191930 191932 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
tabling member	4267 label Biography information for Sarah Champion

1007776

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 June 2018 to Question 153280 on HIV Infection: Drugs, how many women who are victims of domestic violence have joined the HIV pre-exposure prophylaxis impact trial to date.
tabling member constituency	Rotherham
tabling member printed	Sarah Champion
uin	191932
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>In line with the guidance governing research, the HIV Pre-Exposure Prophylaxis (PrEP) Impact Trial is currently unable to provide any detailed breakdown of information about participants. This is to preserve the integrity of the emerging data. A planned interim analysis including further demographic breakdown is planned early next year.</p><p> </p><p>An evaluation report will be available after the completion of the trial in 2021 which is expected to include the facilitators and barriers to accessing HIV pre-exposure prophylaxis across all groups, including women.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 191929 191930 191931 question first answered 20/11/2018 15:03:05 answering member 4067 label Biography information for Steve Brine
tabling member	4267 label Biography information for Sarah Champion

1007777

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Breast Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will introduce a secondary support package covering breast cancer care to include (a) access to a dedicated clinical nurse specialist, (b) an assessment of physical and emotional needs at (i) diagnosis and (ii) through treatment and referral and (c) signposting to tailored, specialist support services.
tabling member constituency	Birkenhead
tabling member printed	Frank Field
uin	191871
answer	answer is ministerial correction date of answer 22/11/2018 answer text <p>The NHS Cancer Programme is working to improve access to cancer nurse specialists (CNSs) for all cancer patients when they need it, including those with secondary breast cancer.</p><p> </p><p>We are committed to rolling out the recovery package to every cancer patient by 2020. The recovery package is a set of four interventions designed to help patients and clinicians assess a patient’s holistic needs, including physical and emotional needs, at appropriate time points through their cancer journey, as needs do change especially when a person is diagnosed with secondary cancer. A personalised care and support plan to meets these needs should be agreed, ensuring signposting and referral to the right support and care services is made, and also helping to empower patients to independently manage their own health, with advice and support.</p><p> </p><p>NHS England is committed to giving more patients access to a CNS or other specialist from diagnosis onwards to guide them through treatment options and ensure they receive appropriate information and support. In their first Cancer Workforce Plan, which was published in December 2017, Health Education England committed to supporting the expansion of CNSs by developing national competencies and a clear route into training. This will ensure that every patient has access to a CNS or other support worker by 2021.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/11/2018 15:20:10 answering member 4067 label Biography information for Steve Brine
tabling member	478 label Biography information for Lord Field of Birkenhead

1007788

registered interest
date	15/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescriptions: Fees and Charges
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many prescription items were dispensed for free in each exemption category in the last period for which figures are available.
tabling member constituency	Cleethorpes
tabling member printed	Martin Vickers
uin	191902
answer	answer is ministerial correction date of answer 22/11/2018 answer text <p>The information is not held in the format requested.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/11/2018 15:11:14 answering member 4067 label Biography information for Steve Brine
tabling member	3957 label Biography information for Martin Vickers